Table 4. Anticoagulation and Outcomes of Atrial Fibrillation with Ibrutinib.
CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism, vascular disease, age, and sex category); HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, and drugs or alcohol); TIA: transient ischemic attack
| Antiplatelet agent or anticoagulants | |||
| All -14 | Atrial fibrillation prior to starting ibrutinib (10) | Atrial fibrillation after starting ibrutinib (4) | |
| Aspirin | 12 (85.71%) | 9 (90%) | 3 (75%) |
| Warfarin | 3 (21.43%) | 3 (30%) | 0 |
| Enoxaparin | 3 (21.43%) | 1 (10%) | 2 (50%) |
| Apixaban | 3 (21.43%) | 2 (20%) | 1 (25%) |
| Changes in antiplatelet or anticoagulation agents | 4 (28.57%) | 3 (30%) (discontinued enoxaparin; discontinued aspirin; discontinued aspirin) | 1 (25%) apixaban dose reduced |
| CHA2DS2-VASc score | % Out of 13 | ||
| 0 | 0 | 0 | 0 |
| 1 | 1 (7.69%) | 1 (11.11%) | 0 |
| 2 | 5 (38.46%) | 5 (55.56%) | 0 |
| 3 | 5 (38.43%) | 3 (33.33%) | 2 (50%) |
| 4 | 2 (15.38%) | 0 | 2 (50%) |
| HAS-BLED score | % Out of 14 | ||
| 1 | 3 (21.43%) | 2 (20%) | 1 (25%) |
| 2 | 8 (57.14%) | 7 (70%) | 1 (25%) |
| 3 | 3 (21.43%) | 1 (10%) | 2 (50%) |
| Outcomes | % Out of 14 | ||
| Stroke (hemorrhagic, ischemic, TIA) | 0 | 0 | 0 |
| Systemic embolism | 1 (7.14%) | 1 (10%) | 0 |
| Bleeding (major [intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome]; minor) | 0 | 0 | 0 |